CLGN Company Profile and Key Details

Q: Who are the executives of CLGN?

Ms. Michal RoytmanVice President of Sales & MarketingMr. Eran Rotem C.P.A.Deputy Chief Executive Officer & Chief Financial OfficerProf. Oded ShoseyovFounder & Chief ScientistDr. Ilana BelzerChief Operations OfficerDr. Elana GazalVice President of R&DMr. Yehiel TalChief Executive Officer & DirectorMr. Eran Rotem CPADeputy Chief Executive Officer & Chief Financial OfficerMr. Oren FahimipoorVice President of OperationsMs. Hadas Dreiher HorowitzVice President of HR

NASDAQ : CLGN

CollPlant Biotechnologies

$1.54

0.0234+1.54%

Open: 2:50 PM

78.38

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

CollPlant Biotechnologies Ltd. (CLGN) stock surged +1.54%, trading at $1.54 on NASDAQ, up from the previous close of $1.52. The stock opened at $1.49, fluctuating between $1.46 and $1.55 in the recent session.

Stock Snapshot

1.5205

Prev. Close

19.63M

Market Cap

1.4601

Day Low

-1.5

P/E Ratio

-1.03

EPS (TTM)

-0.32

Cash Flow per Share

1.49

Open

12.72M

Number of Shares

1.55

Day High

77.18%

Free Float in %

2.47

Book Value

35.04K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 19, 2025	1.40	1.54	1.39	1.52	20.79K
Dec 17, 2025	1.65	1.65	1.41	1.41	32.49K
Dec 16, 2025	1.69	1.69	1.51	1.53	32.28K
Dec 15, 2025	1.79	1.79	1.65	1.67	30.53K
Dec 12, 2025	1.85	1.86	1.76	1.81	24.11K
Dec 11, 2025	1.78	1.93	1.77	1.90	31.56K
Dec 10, 2025	1.78	1.91	1.78	1.81	11.35K
Dec 09, 2025	1.96	2.07	1.77	1.77	70.53K
Dec 08, 2025	2.01	2.08	1.98	2.04	10.25K
Dec 05, 2025	2.01	2.07	2.00	2.01	16.21K
Dec 04, 2025	2.04	2.10	2.00	2.10	12.7K
Dec 03, 2025	2.04	2.08	2.00	2.07	12.62K
Dec 02, 2025	2.07	2.14	2.01	2.14	18.95K
Dec 01, 2025	2.20	2.20	2.05	2.07	39.74K
Nov 28, 2025	2.23	2.25	2.14	2.19	13.45K
Nov 26, 2025	2.05	2.23	1.92	2.23	50.48K
Nov 25, 2025	2.08	2.24	2.08	2.24	18.5K
Nov 24, 2025	2.19	2.22	2.04	2.22	18.11K
Nov 21, 2025	2.05	2.22	2.03	2.22	12.27K
Nov 20, 2025	2.11	2.14	1.99	2.14	7.3K

Contact Details

Rehovot, 7670104

Israel

https://www.collplant.com 972 732 325600

About Company

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

Stock Peers

ARGX

7.94+0.94%

argenx SE$854.99 REGN

19.25+2.57%

Regeneron Pharmaceuticals, Inc.$767.96 MDGL

46.61+8.56%

Madrigal Pharmaceuticals, Inc.$591.02 UTHR

10.13+2.00%

United Therapeutics Corporation$517.13 VRTX

8.82+1.97%

Vertex Pharmaceuticals Incorporated$456.20 ALNY

4.19+1.06%

Alnylam Pharmaceuticals, Inc.$400.23 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

3.66001+1.36%

Praxis Precision Medicines, Inc.$272.92 KRYS

7.43+3.18%

Krystal Biotech, Inc.$240.80 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) closed at $1.54 USD, gaining $0.02 (1.54%) from the previous close of $1.52. The stock is currently mid-range between its 52-week high and low $1.30 and $4.98. With a market capitalization of about $19.63 million, CollPlant Biotechnologies Ltd. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.67). Key stats such as the average daily volume over the past year has been around 101.97 thousand shares, volume is running light vs its 52-week average. Headquartered in Rehovot, None, CollPlant Biotechnologies Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Yehiel Tal, the company employs approximately 57 people and listed since January 31, 2018. CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe.

Technical Performance

CLGN has shown weak momentum, losing -20.0% over the past week and -39.68% over the past quarter, though year-to-date performance is down -57.78%. Short-term trend indicators are bullishly aligned (SMA20 -20.68%, SMA50 -27.02%, SMA200 -32.85%). The stock’s 14-day RSI is 33.28 (weak momentum), while the ATR of 0.16 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -69.48% below its high and over 16.92% above its low. Average 10-day trading volume of 28.04 thousand shares is below the 3-month average of 100.07 thousand, indicating normal recent market interest.

Valuation Metrics

CollPlant Biotechnologies Ltd. trades at a P/E ratio of -1.59, slightly below the S&P 500 average, with a price-to-sales ratio of 7.81 and a price-to-book ratio of 2.08 suggesting the stock is closer to book value. The P/FCF stands at -1.93, also above market averages.

Dividend & Fair Value

CollPlant Biotechnologies Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.25. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

CollPlant Biotechnologies Ltd. generated EPS of -$1.02 over the past year. Five-year average earnings growth is 8.32%. Wall Street analysts project EPS growth of 47.74% annually over the next five years. The latest quarter delivered EPS of -$0.27. The next quarter is forecast at -$0.07. Next year's EPS is expected at -$97.17. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $11.00. The high target offers 821.05% upside. The low target suggests 623.68% downside. The mean target is $12.62. This offers 730.26% upside. CollPlant Biotechnologies Ltd. earnings surprise history is a mixed track record. The quarter that ended November 26, 2025, missed forecasts by -171.05%. The prior quarter beat by 180.0%. Over the last six quarters, Apple has recorded several small beats. These include 108.57% in August 20, 2024.

Shareholding & Insider Activity

CollPlant Biotechnologies Ltd. has 12.72 million shares outstanding. The public float is 8.91 million shares, elevated short interest at 0.71% of float. This equals 63.71 thousand shares. The short ratio is 1.27 days. Institutional investors hold 13.62% of the float. Insiders own 10.16%.

Financial & Profitability Overview

Over the trailing twelve months, CollPlant Biotechnologies generated $10.96M in revenue, or $0.96 per share. Gross margin was 71.78%, operating margin -68.55%, and net profit margin -64.05%. Returns are negative, with ROA at -20.57% and ROE at -24.77%.
On valuation metrics, CollPlant Biotechnologies trades at a P/E of -1.59, P/S of 7.81 and P/B of 2.08. The current ratio is 3.66 and quick ratio is 3.45. Operationally, the company’s inventory turnover is 3.43 and cash conversion cycle is -13.74 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.32, supported by a cash flow-to-debt ratio of -3.38.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, CollPlant Biotechnologies posted revenue of $10.96M, down slightly from $299.00K in the prior quarter. Gross profit was $7.87M (margin 71.78%). Operating income was - $7.51M (margin -68.5%). Net income was- $7.02M (EPS - $0.62).
The company ended the quarter with $26.92M in cash and short-term investments, a total debt of $3.16M, and net debt of - $23.76M. Total assets were $34.13M, with equity of $28.34M. Financials further reflected weakness, with operating cash flow of - $2.76M, free cash flow of - $3.72M, and capital expenditures of - $954.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that CollPlant Biotechnologies Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -25.0%, with price expected at $1.14 by January 02, 2026, within a range of $1.02 to $1.27 3-Month Outlook: Projected fall of -43.42%, reaching $0.86 by March 19, 2026, with a range of $0.74 to $0.97. 1-Year Outlook: Projected gain of 78.29%, with price at $2.71 by December 18, 2026, within a range of $0.53 to $2.72.

Key Takeaways

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) shares are down -57.78% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows CollPlant Biotechnologies Ltd. trading at a premium to the broader market with a P/E of -1.59. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.05, suggesting 758.55% upside. Our AI forecast model points to short-term weakness (-25.0% over two weeks), a medium-term fall (-43.42% over three months), and a longer-term gain (78.29% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current CollPlant Biotechnologies Ltd. (CLGN) stock price?

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) stock price is $1.54 in the last trading session. During the trading session, CLGN stock reached the peak price of $1.55 while $1.46 was the lowest point it dropped to. The percentage change in CLGN stock occurred in the recent session was 1.54% while the dollar amount for the price change in CLGN stock was $0.02.

CLGN's industry and sector of operation?

The NASDAQ listed CLGN is part of Biotechnology industry that operates in the broader Healthcare sector. CollPlant Biotechnologies Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CLGN?

Ms. Michal Roytman
Vice President of Sales & Marketing
Mr. Eran Rotem C.P.A.
Deputy Chief Executive Officer & Chief Financial Officer
Prof. Oded Shoseyov
Founder & Chief Scientist
Dr. Ilana Belzer
Chief Operations Officer
Dr. Elana Gazal
Vice President of R&D
Mr. Yehiel Tal
Chief Executive Officer & Director
Mr. Eran Rotem CPA
Deputy Chief Executive Officer & Chief Financial Officer
Mr. Oren Fahimipoor
Vice President of Operations
Ms. Hadas Dreiher Horowitz
Vice President of HR

How CLGN did perform over past 52-week?

CLGN's closing price is 16.92% higher than its 52-week low of $1.30 where as its distance from 52-week high of $4.98 is -69.48%.

How many employees does CLGN have?

Number of CLGN employees currently stands at 57.

Link for CLGN official website?

Official Website of CLGN is: https://www.collplant.com

How do I contact CLGN?

CLGN could be contacted at phone 972 732 325600 and can also be accessed through its website. CLGN operates from Weizmann Science Park, Rehovot, 7670104, Israel.

How many shares of CLGN are traded daily?

CLGN stock volume for the day was 35.04K shares. The average number of CLGN shares traded daily for last 3 months was 101.97K.

What is the market cap of CLGN currently?

The market value of CLGN currently stands at $19.63M with its latest stock price at $1.54 and 12.72M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	57
Beta	0.67
Sales or Revenue	$10.96M
5Y Sales Change%	-0.119%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CLGN Company Profile and Key Details

CollPlant Biotechnologies

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways